We would like to share with you the extensive experience of one of distributor through the words of Vincenzo Iezzi, Scientific Pharmaceutical Representative of Ecupharma. In this short interview Vincenzo describes the main features of Cogiton, our clinically tested and patented food supplement for the central nervous system health.

Hi Vincenzo, thank you for joining us. We would like to know what is Cogiton and how you present the product to the physicians expert in the CNS field?

Cogiton is a food supplement with a specific action on central nervous system functions. Its specificity is linked to its unique composition: ginkgo biloba, carnosine, B vitamins (B1, B2, B3, B6, B9, B12), and the antioxidant complex (Vit. E, Vit. C, β-carotene, Coenzyme Q10, Selenium, L-Cysteine).

The presentation to the neurologists always starts from epidemiological evidence. There is a constant global increase in the elderly population and, as age progresses, there is a decline in cognitive functions. Cognitive decline is a public health threat because it invariably evolves into Mild Cognitive Impairment (MCI), Alzheimer’s Disease (AD), and other types of dementia, with relevant consequences on healthcare and socio-economic aspects.

Among the etiopathogenetic factors of cognitive decline, today increasing attention is being paid to oxidative stress (OS). The brain is characterized by a predominant glucose metabolism with high consumption of Glucose and O2, that causes the continuous formation of reactive oxygen species (ROS) able to oxidize lipids, proteins, and nucleic acids, damaging cells. Under normal conditions, ROS-induced damage is counteracted by the endogenous antioxidant systems. However, the progressive age-dependent reduction of these defences creates a condition of imbalance between oxidative processes of metabolic origin and the antioxidant capacities of cells. Under these conditions, vicious circles can be established by inducing homocysteine accumulation, a known risk factor for vascular and neurodegenerative diseases. Homocysteine is characterized by pro-oxidant activities that can lead to endothelial dysfunction and amplify ROS formation.

Finally, the high level of circulating glucose is responsible for glycation processes of cellular proteins: glycated proteins lose some of their properties, with significant consequences on metabolism and cellular functions. Their accumulation results in cell apoptosis.

Cogiton represents the specific and comprehensive solution to improve symptoms related to premature aging and oxidative stress. Indeed, the unique combination of its ingredients allows Cogiton to perform with specific, synergistic and harmonized actions:

Ginkgo Biloba contributes to cell protection from oxidative stress, acts effectively on memory and cognitive function, and preserves normal blood circulation and microcirculation function. It reduces blood viscosity by inhibiting PAF (platelet activating factor).

Carnosine possesses free radical scavenger activity and counteracts protein glycation phenomena.

Vitamins B1, B2, B3, B6, B9, B12 modulate homocysteine levels (neurodegenerative and cardiovascular risk factor), improve the efficiency of antioxidant defences by intervening in cellular metabolism, and promote cysteine synthesis.

In this type of chronic disease, early intervention can be critically important. In this context, how difficult is it for clinicians to intervene early and how can Cogiton help?

The human brain is the last organ to complete anatomical and functional development, but it is also the first to begin aging. It possesses 20 to 100 billion nerve cells. Of these it loses about 10,000 per day until age 25 and 100,000 per day from age 25 to 45, after that age the daily loss increases further. The first anatomical changes that indicate brain aging would begin as early as around 25 to 30 years of age and affect the number of neurons, the connections between them and their functioning. In this context, the role of oxidative stress and glucose metabolism is undeniable.

Physicians are ready to consider these aspects and implement appropriate intervention strategies. They are aware that the proportion of elderly among their patients is steadily increasing, but unfortunately, they often have time and resources to focus only on chronic diseases (e.g. cardiovascular, prostatic, respiratory, etc.), having less time to adopt strategies to counteract the initial stages of aging processes. Few family physicians offer their patients therapies to improve brain aging symptoms. When the patient comes to the neurologist’s attention, often the deficits are very pronounced and the margins for intervention are narrower, as the use of anti-dementia drugs and possibly synergistic supportive therapies have reduced efficacy in these cases. Some specialists manage to enrol elderly patients earlier and treat them with Cogiton. In these cases, the feedback is positive, first because several patients show improvements, especially in attention and working memory, but also because patients with pronounced cognitive impairment (on MMSE assessments) do not get worse in the long-term. The positive feedback is also shared by family members and caregivers.

What do you think are the main features of Cogiton and the most important aspects when the product is employed?

Cogiton is certainly the most specific and comprehensive food supplement among the ones indicated for cognitive impairment. Physicians, patients and especially their caregivers recognize, albeit with different nuances, its effectiveness and ability to improve quality of life. The most critical aspect is the timing of intervention. By the time the patient is referred for treatment, they are often already beyond MIC, and therapeutic intervention can only maintain the baseline condition or slow its worsening. As some experts say, the problem is cultural: we need to work in prevention and treat cognitive impairment when there is no evidence of it yet.

Cogiton counteracts the deleterious effects of oxidative stress and of the related aging processes. Use in prevention (as a nootropic) can further improve the  quality of life of patients and their caregivers.